Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sleep Wake Disorders 1Fatigue 1Depression 1Cognition Disorders 1Breast Neoplasms 1Anxiety Disorders 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has results × Donepezil × Clear all
NCT01466270 2021-10-20

Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

Wake Forest University Health Sciences

Phase 2 Completed
62 enrolled 12 charts
Breast

Anxiety Disorders, Breast Neoplasms, Cognition Disorders, Depression, Fatigue, Sleep Wake Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡